Blinatumomab
Myeloproliferative Neoplasm
The First Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
46 Active assets in the Myeloproliferative Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Decitabine Jacqueline Garcia, MD | Phase 2 | BB |
Azacitidine Prelude Therapeutics | Phase 2 | BB |
Cytosin-Arabinosid Fred Hutchinson Cancer Center | Phase 3 | BB |
Cladribine M.D. Anderson Cancer Center | Phase 2 | BB |
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Fred Hutchinson Cancer Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →